Nassim Usman, Barry Polisky, Mark Roellig, and Katherine High | GenomeWeb

Sirna Therapeutics said this week that Nassim Usman, senior vice president and COO, is leaving the company to pursue other interests.

Sirna also announced that Barry Polisky, vice president of research, has also been named CSO.

Polisky joined Sirna in 2002 from NeXstar Pharmaceuticals, where he was vice president of research.


Fisher Scientific said this week that Mark Roellig has joined the company as vice president, general counsel, and secretary.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.